Brief: Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial

Allakos

25/06/2024 21:24

June 25 (Reuters) - Allakos Inc  ALLK.O :
    * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE
1
TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING
HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY
PROFILE
    * ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE
SAFETY
PROFILE
    * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE
SAFETY
PROFILE -
    * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE
SAFETY
PROFILE
    * ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS
CONSISTENT
WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL
EXPERIMENTS
    * ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH
AN
ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE
    * ALLAKOS-  IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM
CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL
INHIBITION IN PRECLINICAL EXPERIMENTS

Source text for Eikon:  ID:nGNX6rGfGW 
Further company coverage:  ALLK.O 

 ((reuters.briefs@thomsonreuters.com;))